Please complete the CAPTCHA to continue
@adastrarx.com
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
Scott Megaffin is listed as Chief Executive Officer, Board Member, Adiso Therapeutics at Adiso Therapeutics, based in New York City Metropolitan Area, United States. AeroLeads shows a work email signal at adastrarx.com and a matched LinkedIn profile for Scott Megaffin.
Scott Megaffin previously worked as Member Board Of Directors - Former Chief Executive Officer at Adastra Pharmaceuticals, Inc. and President at Churchill Pharmaceuticals Llc. Scott Megaffin holds Bachelor Of Science - Bs, Biology, 1984 from Pittsburg State University.
This section adds company-level context without repeating Scott Megaffin's masked contact details.
AeroLeads found 1 current-domain work email signal for Scott Megaffin. Compare company email patterns before reaching out.
✔Strategy ✔Change Leadership ✔Commercial Innovation ✔Execution ✔Global M&AProven C-level leader with deep experience running global Fortune 500, start-up, and emerging pharmaceutical businesses, possessing the unique ability to blend, build, and strengthen performance from the ground up. Broad understanding of market strategy development within clinically diverse programs that achieve meaningful product differentiation. Significant accomplishments creating profitable business development and investment community partnerships within the C-suite. Strategy/Vision: Deep start-up, transaction and capital raising success through the establishment and guidance of Adiso, Adastra, and Churchill; creation and execution of clinical development and business strategy to lead the companies from formation; with the identification and advancement of multiple first-in-class drug product assets; negotiated and managed lucrative business development partnerships; business development and licensing with Baxalta, transaction to Cothera Bioscience and Sun Pharma FZE.Change Leadership: Adaptable and insightful leader instrumental in the cultural and team transformation of Onconova from a private 16-person medicinal chemistry company into a commercially prepared 67-employee Nasdaq listed company executing a successful Initial Public Offering (IPO). Commercial Innovation: Directly involved in numerous successful product development/co-development programs and commercial launches within oncology and specialty therapeutics. Demonstrated ability to employ unique approaches to value pricing and contracting within competitive markets. Execution/Implementation: Ability to visualize and articulate both long-term and near-term goals while promoting excellence through organization design, leverage of key functional areas, with clear decision making and process application. Global M&A: Marshalled Churchill Pharma through nine-month transaction process and successful sale of assets prior to product approval by FDA, while simultaneously preparing for a Churchill launch. While at Onconova, initiated and negotiated two separate license agreements for Japan/Korea and Europe
Listed skills include Oncology, Pharmaceutical Industry, Product Launch, Biotechnology, and 45 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Concord, Massachusetts, Us
Honored to lead an exceptional, world-class, and dedicated team in the development of highly unique therapies designed to precisely halt the dysregulation generated by inflammatory diseases.
Princeton, New Jersey, Us
Board Member, Adastra Pharmaceuticals; guiding the company to a successful transaction to Cothera Bioscience in 2021.
King Of Prussia, Pa, Us
Led all corporate finance, fundraising, operations, staffing, and cross-functional preparation for the launch and commercialization of Yonsa [SoluMatrix Abiraterone Acetate (SAA)] and other products. Managed all business and corporate development activities to build Churchill into an oncology/urology commercialization company. As President of Churchill Pharmaceuticals, LLC, I had the opportunity to work with an extremely talented group of high performers who rapidly built an exciting pharmaceutical company with innovative therapies which merged medicine with technology, possessing the potential to transform future oncology drug development. At Churchill we focused our effort on cancers that are highly prevalent and needed alternative treatments. Yonsa, the most advanced Churchill pipeline product was approved by the US FDA in May of 2018. This product has the potential to fundamentally change how therapy is undertaken and provided to the community at large as a benefit to the healthcare system and to patients, as well as how it is distributed and reimbursed. This disruptive new approach holds significant promise as a 'game-changing' treatment in this increasingly common and important disease, and requires our team to apply a new level of thinking and acting. Beginning in early 2015 and working hard through 2018, tremendous forward progress took place at Churchill, including building a world-class team, the opening of new headquarters in King of Prussia, PA, and the diversification of expertise into a team that made things happen. A key element of pride during Churchill’s progress was been our ability to remain fully private and independent through multiple rounds of financing, ensuring so that we continued to have strategic and executional control over their rapidly evolving business.Additional information about Churchill can be found at http://www.churchillpharma.com/.
Newtown, Pa, Us
Private company focused on discovering and developing novel small molecule drug candidates to treat cancer.Led commercial development function to build and expand corporate value within small, expanding oncology company, growing from medicinal chemistry phase through clinical development and into commercial readiness. Developed the strategic positioning and financial value assessment globally for rigosertib, a small molecule Raf binding domain RAS mimetic.
Us
Global biopharmaceutical company (NYSE: TEVA).Led specialty care marketing, market research, commercial operations, managed markets, and sales cross-functional team. Ignited portfolio management and developed enhanced strategies of key franchise brands Fentora, Actiq, and Amrix through clinically meaningful and competitively differentiated clinical trial planning. Held full P&L, forecasting and financial oversight for Primary Care and Specialty businesses.
Us
Developed and executed the go-to-market strategy for a mu-opioid antagonist, Entereg (alvimpopan). Built commercialization and development collaborations with GSK and Pfizer. Built business development, commercial operations, sales, market research, and marketing teams from inception.
Rahway, New Jersey, Us
Now MERCK & COMPANY, NYSE: MRKRecruited to turn around declining global market performance in a billion-dollar franchise. Led a global GI/hepatitis marketing team and co-led Regulatory, Medical Affairs, Clinical, Health Outcomes, Manufacturing, BD, and Biostatistics global life-cycle management team. Developed a globally unified strategic brand approach based upon a powerful patient-centric strategy and grew revenue of global franchise, expanding market share growth year-on-year in a declining market.
YAMANOUCHI (now ASTELLAS PHARMA), Paramus, NJ Developed the global commercialization strategy for Vaprisol® (conivaptan hydrochloride), a vasopressin antagonist, a first-in-class product in a first-to-be-indicated medical condition (hyponatremia).
New York, New York, Us
NYSE: PFE (Merged with PFIZER)Led North American business for Dynastat®. Oversaw all strategic planning for and promotional messaging for the US, Canada, and Puerto Rico.
Lawrence Township, Nj, Us
NYSE: BMYSenior Product Manager, Infectious Disease – Tequin® & Cefzil (1998–2001)District Business Manager, Florida Region (1995–1998)Region Sales Trainer, Florida (1994 – 1995)Senior Institutional Business Manager, Texas (1993 – 1994)Associate Manager Region Operations, Texas Region (1991 – 1993)Sales Representative (1988 – 1990)
Quick answers generated from the profile data available on this page.
Scott Megaffin works for Adiso Therapeutics.
Scott Megaffin is listed as Chief Executive Officer, Board Member, Adiso Therapeutics at Adiso Therapeutics.
AeroLeads has found 1 work email signal at @adastrarx.com for Scott Megaffin at Adiso Therapeutics.
Scott Megaffin is based in New York City Metropolitan Area, United States while working with Adiso Therapeutics.
Scott Megaffin has worked for Adiso Therapeutics, Adastra Pharmaceuticals, Inc., Churchill Pharmaceuticals Llc, Onconova, and Cephalon.
You can use AeroLeads to view verified contact signals for Scott Megaffin at Adiso Therapeutics, including work email, phone, and LinkedIn data when available.
Scott Megaffin holds Bachelor Of Science - Bs, Biology, 1984 from Pittsburg State University.
Scott Megaffin is listed with skills including Oncology, Pharmaceutical Industry, Product Launch, Biotechnology, Clinical Trials, Clinical Development, Strategic Planning, and Managed Care.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts